AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine. It also develops ABP-450 for the treatment of gastroparesis and post-traumatic stress disorder. The company has license agreements Daewoong Pharmaceutical Co., LTD., and Viatris Inc. The company is based in Irvine, California.…
AEON Biopharma Submits IND for Comparative Pharmacodynamic Study of ABP-450
AEON Biopharma (NYSEAMERICAN: AEON) is listed on NYSE American, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 8 employees.
The shares were at 0.1230 USD on 20 November 2026, down 89.4% over 52 weeks. Its 52-week range is 0.1072 USD to 1.450 USD: the price is 91.5% below the high and 14.7% above the low.
Its market capitalisation is 10.35M USD.
AEON Biopharma reports return on equity of 71.3% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 8.63M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.